These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 28084558)

  • 1. PCSK9 in chronic kidney disease.
    Pavlakou P; Liberopoulos E; Dounousi E; Elisaf M
    Int Urol Nephrol; 2017 Jun; 49(6):1015-1024. PubMed ID: 28084558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K; Park BS; Kim YW; Vaziri ND
    Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism.
    Morena M; Le May C; Chenine L; Arnaud L; Dupuy AM; Pichelin M; Leray-Moragues H; Chalabi L; Canaud B; Cristol JP; Cariou B
    J Clin Lipidol; 2017; 11(1):87-93. PubMed ID: 28391915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy.
    Konarzewski M; Szolkiewicz M; Sucajtys-Szulc E; Blaszak J; Lizakowski S; Swierczynski J; Rutkowski B
    Am J Nephrol; 2014; 40(2):157-63. PubMed ID: 25171595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease.
    Vlad CE; Foia L; Popescu R; Ivanov I; Luca MC; Delianu C; Toma V; Statescu C; Rezus C; Florea L
    J Diabetes Res; 2019; 2019():6906278. PubMed ID: 31915710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of cardiovascular events and progression to end-stage renal disease in patients with dyslipidemia and chronic kidney disease from the North-Eastern area of Romania.
    Vlad CE; Foia L; Pavel-Tanasa M; Toma V; Florea L; Voroneanu L; Apetrii M; Dodi G; Covic A
    Int Urol Nephrol; 2022 Mar; 54(3):647-659. PubMed ID: 34224064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR.
    Rogacev KS; Heine GH; Silbernagel G; Kleber ME; Seiler S; Emrich I; Lennartz S; Werner C; Zawada AM; Fliser D; Böhm M; März W; Scharnagl H; Laufs U
    PLoS One; 2016; 11(1):e0146920. PubMed ID: 26799206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and Estimated Glomerular Filtration Rate in the General Chinese Population.
    Zhang HW; Zhao X; Xu RX; Guo YL; Zhu CG; Wu NQ; Cui CJ; Dong Q; Li JJ
    Cardiorenal Med; 2018; 8(4):311-320. PubMed ID: 30121647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients.
    Dounousi E; Tellis C; Pavlakou P; Duni A; Liakopoulos V; Mark PB; Papagianni A; Tselepis AD
    Oxid Med Cell Longev; 2021; 2021():6677012. PubMed ID: 34336112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein convertase subtilisin/kexin type 9 targets megalin in the kidney proximal tubule and aggravates proteinuria in nephrotic syndrome.
    Skeby CK; Hummelgaard S; Gustafsen C; Petrillo F; Frederiksen KP; Olsen D; Kristensen T; Ivarsen P; Madsen P; Christensen EI; Nielsen R; Birn H; Glerup S; Weyer K
    Kidney Int; 2023 Oct; 104(4):754-768. PubMed ID: 37406929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.
    Haas ME; Levenson AE; Sun X; Liao WH; Rutkowski JM; de Ferranti SD; Schumacher VA; Scherer PE; Salant DJ; Biddinger SB
    Circulation; 2016 Jul; 134(1):61-72. PubMed ID: 27358438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 in diabetic kidney disease.
    Elewa U; Fernández-Fernández B; Mahillo-Fernández I; Martin-Cleary C; Sanz AB; Sanchez-Niño MD; Ortiz A
    Eur J Clin Invest; 2016 Sep; 46(9):779-86. PubMed ID: 27438893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arylesterase activity but not PCSK9 levels is associated with chronic kidney disease in type 2 diabetes.
    Didas N; Thitisopee W; Porntadavity S; Jeenduang N
    Int Urol Nephrol; 2020 Sep; 52(9):1725-1732. PubMed ID: 32661629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels.
    Abujrad H; Mayne J; Ruzicka M; Cousins M; Raymond A; Cheesman J; Taljaard M; Sorisky A; Burns K; Ooi TC
    Atherosclerosis; 2014 Mar; 233(1):123-9. PubMed ID: 24529132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment.
    Tsimihodimos V; Dounousi E; Siamopoulos KC
    Am J Nephrol; 2008; 28(6):958-73. PubMed ID: 18612199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.
    Vaziri ND; Norris KC
    Blood Purif; 2013; 35(1-3):31-6. PubMed ID: 23343544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCSK9 and Cardiovascular Disease in Individuals with Moderately Decreased Kidney Function.
    Kheirkhah A; Lamina C; Kollerits B; Schachtl-Riess JF; Schultheiss UT; Forer L; Sekula P; Kotsis F; Eckardt KU; Kronenberg F;
    Clin J Am Soc Nephrol; 2022 Jun; 17(6):809-818. PubMed ID: 35387881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of dyslipidemia and oxidative stress on vasoactive mediators in patients with renal dysfunction.
    Jabarpour M; Rashtchizadeh N; Argani H; Ghorbanihaghjo A; Ranjbarzadhag M; Sanajou D; Panah F; Alirezaei A
    Int Urol Nephrol; 2019 Dec; 51(12):2235-2242. PubMed ID: 31641998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.
    Ruscica M; Ferri N; Fogacci F; Rosticci M; Botta M; Marchiano S; Magni P; D'Addato S; Giovannini M; Borghi C; Cicero AFG;
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28468788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.